Advertisement
Advertisement
ANIP
ANI Pharmaceuticals, Inc.
81.86
USDSponsored
-2.05
-2.44%
May 08, 15:59 UTC -4
Closed
After-Market
81.84
-0.02
-0.02%
ANIP Earnings Reports
Positive Surprise Ratio
ANIP beat 28 of 42 last estimates.
67%
Next Report
Date of Next Report
Aug 06, 2026
Estimate for Q2 26 (Revenue/ EPS)
$268.70M
/$2.22
Implied change from Q1 26 (Revenue/ EPS)
+13.16%
/+8.82%
Implied change from Q2 25 (Revenue/ EPS)
+27.12%
/+23.33%
ANI Pharmaceuticals, Inc. earnings per share and revenue
On May 08, 2026, ANIP reported earnings of 2.04 USD per share (EPS) for Q1 26, beating the estimate of 1.33 USD, resulting in a 54.04% surprise. Revenue reached 237.46 million, compared to an expected 211.72 million, with a 12.16% difference. The market reacted with a -2.44% price change (close before vs. close after earnings).
Looking ahead to Q2 26, 7 analysts forecast an EPS of 2.22 USD, with revenue projected to reach 268.70 million USD, implying an increase of 8.82% EPS, and increase of 13.16% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Harmony Biosciences Holdings, Inc. Common Stock
Report Date
May 07, 2026 For Q1 26
Estimate
$0.72
Actual
$0.55
Surprise
-24.16%
CytomX Therapeutics, Inc.
Report Date
May 07, 2026 For Q1 26
Estimate
-$0.12
Actual
-$0.10
Surprise
+18.83%
Tectonic Therapeutic, Inc. Common Stock
Report Date
May 07, 2026 For Q1 26
Estimate
-$1.20
Actual
-$1.34
Surprise
-11.07%
ALX Oncology Holdings Inc. Common Stock
Report Date
May 08, 2026 For Q1 26
Estimate
-$0.22
Actual
-$0.17
Surprise
+24.24%
Entera Bio Ltd. Ordinary Shares
Report Date
May 08, 2026 For Q1 26
Estimate
-$0.15
Actual
-$0.07
Surprise
+54.25%
argenx SE - ADR
Report Date
May 07, 2026 For Q1 26
Estimate
$5.47
Actual
$5.52
Surprise
+0.86%
Arrowhead Research Corporation
Report Date
May 07, 2026 For Q2 26
Estimate
-$1.16
Actual
-$0.93
Surprise
+20.32%
ImmunityBio, Inc. Common Stock
Report Date
May 07, 2026 For Q1 26
Estimate
-$0.07
Actual
-$0.09
Surprise
-26.05%
Stoke Therapeutics, Inc. Common Stock
Report Date
May 07, 2026 For Q1 26
Estimate
-$0.84
Actual
-$0.79
Surprise
+6.34%
Werewolf Therapeutics, Inc. Common Stock
Report Date
May 07, 2026 For Q1 26
Estimate
-$0.29
Actual
-$0.28
Surprise
+3.68%
FAQ
What were ANI Pharmaceuticals, Inc.'s earnings and revenue for the latest quarter Q1 2026?
For Q1 2026, ANI Pharmaceuticals, Inc. reported EPS of $2.04, beating estimates by 54.04%, and revenue of $237.46M, 12.16% above expectations.
How did the market react to ANI Pharmaceuticals, Inc.'s Q1 2026 earnings?
The stock price moved down -2.44%, changed from $83.91 before the earnings release to $81.86 the day after.
When is ANI Pharmaceuticals, Inc. expected to report next?
The next earning report is scheduled for Aug 06, 2026.
What are the forecasts for ANI Pharmaceuticals, Inc.'s next earnings report?
Based on 7
analysts, ANI Pharmaceuticals, Inc. is expected to report EPS of $2.22 and revenue of $268.70M for Q2 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement